EMILIA Trial: T-DM1 Appears Helpful in Women with Her2+ Metastatic Breast Cancer
The new agent is a hybrid of an old monoclonal antibody, Herceptin, that’s chemically attached to DM1, a traditional kind of chemotherapy. The preliminary results of this randomized trial are encou…
